P1098: A PHASE II, OPEN-LABEL, MULTICENTER STUDY OF CAPIVASERTIB, A POTENT, ORAL PAN-AKT INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (CAPITAL)

Documenti analoghi

• Hypermetabolic Ipsilateral Supraclavicular and Axillary Lymphadenopathy: Optimal Time Point for Performing an ¹⁸F-FDG PET/CT after COVID-19 Vaccination
  di: Kwadwo Antwi, et al.
  Pubblicazione: (2022-12-01)
• First use of 18F-FDG PET in TEMPI syndrome: can it be used for treatment assessment? A case report
  di: Henri Pasquesoone, et al.
  Pubblicazione: (2023-10-01)
• Comparison of post-COVID-19 vaccination hypermetabolic lymphadenopathy on 18F-fluorodeoxyglucose PET/CT between virus-vector vaccine and mRNA vaccine
  di: Meng-Ting Chiang, et al.
  Pubblicazione: (2023-11-01)
• A Rare Case of Invasive Thyroid Aspergillosis Revealed on ¹⁸F-FDG-PET/CT
  di: Ayoub Jaafari, et al.
  Pubblicazione: (2024-07-01)
• Role and Importance of Pulmonary Function test in Pulmonary Involvement of COVID-19: A Review Study
  di: Amir Behnam Kharazmi, et al.
  Pubblicazione: (2024-07-01)